Challenges and Possibilities for the Biotech Sector

As the heir to a rich history of agricultural and pharmaceutical breakthroughs, biotechnology has a big promise: medications that treat diseases, prevent them, or cure them; new causes of energy like ethanol; and upgraded crops and foods. Additionally, its technologies are helping to address the world’s environmental and cultural challenges.

Regardless of this legacy of success, the industry fronts many problems. A major motive is that general population equity market segments are badly designed for companies whose return and profits be dependent entirely in long-term research projects that can take years to full and may deliver either ancient breakthroughs or utter failures. Meanwhile, the industry’s fragmented structure with scores of small , and specialized players across far-flung disciplines impedes the sharing and integration of essential knowledge. Finally, the system for earning cash intellectual home gives individual firms a motivation to secure valuable methodical knowledge rather than share this openly. It has led to nasty disputes more than research and development, such as the one among Genentech and Lilly over their recombinant human growth hormone or perhaps Amgen and Johnson & Johnson over their erythropoietin drug.

Nevertheless the industry is usually evolving. The various tools of breakthrough discovery have become much more diverse than in the past, with genomics, combinatorial biochemistry and biology, high-throughput verification, and Everything offering opportunities to explore new frontiers. Strategies are also currently being developed to tackle “undruggable” proteins and also to target disease targets whose biology can be not well understood. The challenge now is to integrate these innovations across the range of scientific, technological, and functional websites.

To Top